Nelivaptan (INN) (developmental codename SSR-149,415) is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype. The drug had entered clinical trials for treatment of anxiety and depression. In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.
| Property | Value |
|---|---|
| dbo:abstract |
|
| dbo:casNumber |
|
| dbo:chEMBL |
|
| dbo:fdaUniiCode |
|
| dbo:pubchem |
|
| dbo:thumbnail | |
| dbo:wikiPageID |
|
| dbo:wikiPageLength |
|
| dbo:wikiPageRevisionID |
|
| dbo:wikiPageWikiLink |
|
| dbp:atcPrefix |
|
| dbp:c |
|
| dbp:casNumber |
|
| dbp:chembl |
|
| dbp:chemspiderid |
|
| dbp:cl |
|
| dbp:h |
|
| dbp:iupacName |
|
| dbp:iupharLigand |
|
| dbp:n |
|
| dbp:o |
|
| dbp:pubchem |
|
| dbp:routesOfAdministration | |
| dbp:s |
|
| dbp:stdinchi |
|
| dbp:stdinchikey |
|
| dbp:unii |
|
| dbp:verifiedfields |
|
| dbp:verifiedrevid |
|
| dbp:watchedfields |
|
| dbp:width |
|
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| rdf:type |
|
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:depiction | |
| foaf:isPrimaryTopicOf | |
| is dbo:wikiPageRedirects of | |
| is dbo:wikiPageWikiLink of | |
| is foaf:primaryTopic of |
